{
  "schemaVersion": 2,
  "eyebrow": "Obesity Medicine",
  "title": "Weight Loss Plateau",
  "summary": "A weight-loss plateau usually reflects a new energy-balance equilibrium, adaptive reductions in expenditure, increased appetite, or relaxed adherence. Reassess trajectory, intake, activity, medications, body composition, and treatment intensity before changing therapy; use chronic disease escalation when clinically indicated.",
  "seoDescription": "Physician approach to weight-loss plateaus: distinguish expected adaptation from adherence, medication, and post-bariatric causes, then intensify treatment.",
  "clinicalQuestion": "How should clinicians evaluate and manage a plateau during lifestyle, anti-obesity medication, or post-bariatric weight-loss treatment?",
  "specialty": "Obesity Medicine",
  "audience": "U.S. physicians and medical trainees",
  "tags": [
    "weight loss plateau",
    "obesity treatment",
    "weight regain",
    "anti-obesity medication",
    "bariatric surgery",
    "adaptive thermogenesis"
  ],
  "keyTakeaways": [
    "Expect deceleration rather than linear weight loss: lifestyle-associated plateaus commonly occur by about 6 months, whereas pharmacotherapy-associated plateaus may occur between 6 and 12 months. [15][19]",
    "At a plateau, obtain an updated diet, physical-activity, medication, and behavioral history before attributing the result solely to metabolic adaptation. [15][16][20]",
    "Medication-associated weight gain is a modifiable contributor; review prescription and over-the-counter agents and substitute lower-weight-impact alternatives when feasible. [20]",
    "For adults meeting obesity-pharmacotherapy criteria, add an FDA-approved anti-obesity medication to lifestyle treatment rather than repeatedly intensifying behavioral counseling alone. [1][20]",
    "After bariatric surgery, distinguish inadequate weight loss or weight regain from nutritional and metabolic complications; pharmacologic weight management may be used as an adjunct after clinical reassessment. [17]"
  ],
  "sections": [
    {
      "id": "recognize-the-plateau",
      "eyebrow": "Trajectory",
      "heading": "Determine whether the trajectory is an expected plateau or clinically important regain",
      "intro": "Interpret serial weights against treatment phase and initial response rather than against an expectation of continuous loss.",
      "paragraphs": [
        "A plateau occurs when prior weight loss decelerates to maintenance despite an intended energy deficit. With moderate calorie restriction, patients may report a plateau within 12 weeks; across lifestyle, meal-replacement, very-low-energy-diet, and older medication strategies, weight loss commonly plateaus near 6 months. ACC/AHA guidance cited in clinical summaries describes maximal lifestyle-associated loss at approximately 6 months, followed by maintenance or slow regain. [14][15]",
        "Do not label a plateau as treatment failure solely because loss has slowed. High-intensity behavioral treatment, defined as at least 14 sessions over 6 months, produces mean losses of approximately 5% to 8% at 4 to 6 months; a loss of at least 5% is commonly used as a clinically meaningful response threshold. Compare current weight with baseline, nadir weight, and the patient-specific cardiometabolic target. [1]",
        "A plateau is actionable when it follows a period of loss but prevents attainment of a clinically important target, when weight is rising from nadir, or when obesity-related disease control is worsening. In contrast, stable weight at an individualized target shifts the encounter from further loss to maintenance planning. [15]"
      ],
      "bullets": [
        "Document baseline weight, nadir weight, current weight, time since treatment initiation, and time since nadir at every reassessment.",
        "Separate a stable-weight plateau from recurrent gain; the latter should trigger a focused search for loss of treatment exposure, medication effects, behavioral relapse, or post-bariatric contributors. [15][17]",
        "Screen for discouragement, depressive symptoms, emotional eating, and psychological distress when a plateau is accompanied by reduced engagement; these factors can further erode dietary adherence. [16]"
      ],
      "subsections": [],
      "table": {
        "caption": "Timing patterns that help frame reassessment of a weight-loss plateau. [14][15][19]",
        "columns": [
          "Treatment context",
          "Typical trajectory",
          "Clinical implication"
        ],
        "rows": [
          [
            "Moderate calorie restriction",
            "Plateau may be reported within 12 weeks. [14]",
            "Reassess actual intake, satiety, eating pattern, and follow-up intensity early rather than assuming continued linear loss."
          ],
          [
            "Lifestyle treatment",
            "Weight loss commonly plateaus around 6 months; maximal loss is generally reached near 6 months, followed by maintenance or slow regain. [14][15][19]",
            "Shift from initial loss targets to adherence recovery and a maintenance-capable treatment plan."
          ],
          [
            "Anti-obesity pharmacotherapy",
            "Plateaus typically occur later than with lifestyle intervention, between 6 and 12 months. [15]",
            "Confirm continued medication exposure and lifestyle support before judging drug response or changing treatment."
          ],
          [
            "After bariatric surgery",
            "Inadequate loss or regain requires postoperative medical reassessment; lifestyle or psychological support alone has shown limited efficacy in small studies. [17]",
            "Evaluate postoperative nutritional and metabolic status and consider adjunct medical weight management when appropriate. [17]"
          ]
        ]
      }
    },
    {
      "id": "reassess-reversible-drivers",
      "eyebrow": "Initial Workup",
      "heading": "Reassess energy intake, activity, treatment exposure, and weight-promoting drugs",
      "intro": "The first intervention is a structured reassessment, not automatic caloric escalation or medication switching.",
      "paragraphs": [
        "Obtain an updated dietary-intake and physical-activity history that specifically compares current behavior with the period of maximum weight loss. Ask about portion drift, caloric beverages, alcohol, restaurant meals, unplanned snacks, weekends, binge or emotional eating, reduced meal structure, step-count decline, resistance-training interruption, and changes in sleep or work schedule. Even intermittent nonadherence can create weight fluctuations or an apparent plateau, and progressive relaxation of dietary adherence is a major driver of plateaus in modeling and clinical summaries. [15][16]",
        "Review treatment exposure with the same rigor used for other chronic therapies: attendance at behavioral sessions, use of food or meal planning, medication persistence, dose changes, adverse effects, supply access, and self-directed dose interruptions. Behavioral support improves long-term outcomes, while adherence to the dietary program strongly influences maintenance. [19]",
        "Perform a complete prescription, nonprescription, and supplement medication review. Weight gain can be induced by drugs used for type 2 diabetes, hypertension, depression, schizophrenia, and insomnia; when clinically feasible, select alternatives with less weight-promoting effect rather than attempting to overcome iatrogenic gain with greater dietary restriction alone. [20]",
        "Address the plateau without framing it as a willpower failure. Weight loss increases appetite and is accompanied by lower energy expenditure and hormonal changes that defend body weight; this biology makes the prior calorie prescription less effective at the lower body mass. Patient education and closer professional follow-up can limit demoralization and treatment dropout. [15][16]"
      ],
      "bullets": [
        "Compare a 7-day contemporaneous food record or structured intake review with the successful early-loss period; use the discrepancy to define one or two measurable dietary changes.",
        "Review physical activity quantitatively using available step-count, exercise-session, or wearable data; prescribe recovery of the prior activity pattern when it was associated with ongoing loss.",
        "Ask directly about medication access, missed doses, and adverse effects before declaring pharmacologic nonresponse.",
        "Replace or minimize a weight-promoting drug only after balancing the indication, efficacy, psychiatric stability, glycemic control, and available alternatives. [20]"
      ],
      "subsections": [],
      "table": null
    },
    {
      "id": "address-physiologic-adaptation",
      "eyebrow": "Mechanism",
      "heading": "Treat the lower-weight state as a new maintenance physiology",
      "intro": "A plateau reflects dynamic energy balance, not invalidation of energy-balance principles.",
      "paragraphs": [
        "As body mass falls, energy requirements decline; a previous caloric deficit can become a maintenance intake. Weight loss also produces adaptive thermogenesis, a disproportionate reduction in energy expenditure relative to body-mass change, together with increased appetite. The practical consequence is that the successful initial plan often requires renewed behavioral structure and a revised long-term treatment intensity. [14][15][16]",
        "Protect lean mass while pursuing further loss. Weight reduction from dietary, behavioral, pharmacologic, surgical, or disease-related causes includes lean-mass loss; across reviewed cohorts, lean mass represented 5.9% to 26.1% of weight lost with dietary, behavioral, and pharmacologic interventions and 19.2% to 23.6% after surgical weight loss. Lean mass is not synonymous with muscle mass, but loss of muscle contributes to lower resting energy expenditure. [8]",
        "Use physical activity as a maintenance tool rather than as a presumed substitute for dietary adherence. Clinical summaries identify high levels of physical activity, close follow-up, psychological support, and dietary adjustments as useful strategies during plateau management, while the behavioral plan remains central because adherence largely determines long-term maintenance. [16][19]"
      ],
      "bullets": [
        "Explain that increased hunger and a lower energy requirement are expected after weight loss; pair this explanation with a concrete plan for food structure and follow-up. [15][16]",
        "Include resistance exercise within an individualized activity program when preserving functional muscle mass is a priority, particularly in older adults or patients with reduced reserve; weight-loss-associated lean-mass loss is clinically relevant in these groups. [4][8]",
        "Avoid interpreting a plateau as evidence that the patient has stopped benefiting if weight remains below baseline and cardiometabolic outcomes are improving."
      ],
      "subsections": [],
      "table": null
    },
    {
      "id": "escalate-chronic-treatment",
      "eyebrow": "Treatment Escalation",
      "heading": "Escalate obesity treatment when lifestyle therapy no longer achieves the clinical target",
      "intro": "Use anti-obesity medication as chronic adjunctive therapy when eligibility and treatment goals support escalation.",
      "paragraphs": [
        "Adults with BMI at least 30 kg/m², or BMI at least 27 kg/m² plus at least one obesity-related complication, are candidates for FDA-approved anti-obesity medication in addition to lifestyle counseling. Expert recommendations have historically positioned medication after dietary, exercise, and behavioral approaches have begun and a target has not been reached or a plateau has occurred. [1][20]",
        "Do not delay escalation until repeated lifestyle-only cycles have failed if the patient remains eligible and has not achieved a clinically meaningful response. In a randomized trial of behavioral-treatment early nonresponders, adding an anti-obesity medication increased mean weight loss compared with behavioral treatment alone; high-intensity behavioral treatment alone typically yields mean loss of 5% to 8% by 4 to 6 months. [1]",
        "Medication selection and dosing require current product labeling, contraindication review, comorbidity-based selection, adverse-effect counseling, and shared decision-making; no source-supported dose-specific regimen is available here. Reassess weight trajectory, medication persistence, tolerability, and obesity-related complications rather than continuing an ineffective or inaccessible regimen without a defined response review. [20]",
        "For patients at a plateau on medication, first verify that the current regimen is being taken as intended and that dietary and activity supports remain active. A pharmacotherapy plateau between 6 and 12 months can represent expected adaptation rather than abrupt loss of drug effect; the next decision is individualized continuation, modification, or escalation according to achieved benefit, tolerability, and patient goals. [15][20]"
      ],
      "bullets": [
        "Add pharmacotherapy to, not instead of, reduced-calorie nutrition, physical activity, and behavioral strategies. [1][20]",
        "Use baseline and serial percentage weight change to define benefit in a shared treatment plan; at least 5% loss is a common clinically meaningful benchmark. [1]",
        "Revisit cardiometabolic goals at each plateau: a stable lower weight may still represent meaningful benefit even when additional loss has stopped. [1][19]"
      ],
      "subsections": [],
      "table": null
    },
    {
      "id": "post-bariatric-plateau",
      "eyebrow": "Postoperative Care",
      "heading": "Evaluate post-bariatric plateau or regain for nutritional, metabolic, and treatment needs",
      "intro": "Postoperative management requires surveillance for complications alongside management of recurrent obesity.",
      "paragraphs": [
        "After Roux-en-Y gastric bypass or sleeve gastrectomy, a plateau or weight regain warrants review of dietary pattern, behavioral symptoms, physical activity, medication exposure, and obesity pharmacotherapy options. Observational evidence suggests that medical weight-loss therapy can assist with post-bariatric inadequate loss or regain, whereas lifestyle or psychological interventions alone have generally shown limited effectiveness in the small studies summarized. [17]",
        "Obtain postoperative laboratory surveillance including 25-hydroxyvitamin D, calcium, albumin, phosphorus, and parathyroid hormone. Titrate vitamin D supplementation to maintain 25-hydroxyvitamin D at least 30 ng/mL. If secondary hyperparathyroidism persists after vitamin D optimization, inadequate calcium intake or absorption is likely; a low 24-hour urinary calcium supports that interpretation and should prompt increased calcium intake with follow-up laboratory testing. Interpret parathyroid hormone in the context of renal function. [17]",
        "Do not manage recurrent obesity after surgery as an isolated weight problem. During active postoperative loss, antihypertensive and glucose-lowering medication requirements may fall; after weight stabilization, hypertension can recur. Reassess blood pressure and glycemic therapy as weight trajectory changes rather than assuming preoperative requirements persist. [19]"
      ],
      "bullets": [
        "Order 25-hydroxyvitamin D, calcium, albumin, phosphorus, and parathyroid hormone during postoperative reassessment. [17]",
        "Target 25-hydroxyvitamin D of at least 30 ng/mL when titrating replacement. [17]",
        "Use a low 24-hour urinary calcium to support inadequate calcium intake or absorption when secondary hyperparathyroidism persists despite optimized vitamin D. [17]",
        "Consider medical weight-management therapy as an adjunct for inadequate postoperative loss or regain after reassessment. [17]"
      ],
      "subsections": [],
      "table": null
    },
    {
      "id": "monitor-maintenance",
      "eyebrow": "Follow-up",
      "heading": "Convert plateau management into a maintenance plan",
      "intro": "Maintenance requires continued surveillance because biologic and behavioral pressures toward regain persist.",
      "paragraphs": [
        "Schedule ongoing follow-up after the plateau rather than ending active care at the first stable weight. Weight regain is common after all major weight-loss modalities, and the chronic reduction in energy expenditure and rise in appetite create continuing relapse pressure. Continued behavioral support improves outcomes and should be paired with longitudinal medication and comorbidity review when pharmacotherapy is used. [2][8][19]",
        "At each follow-up, track weight trajectory, dietary structure, activity, treatment adherence, adverse effects, mood or emotional eating, and the obesity-related complication that justified treatment. Adjust antihypertensive and glucose-lowering therapy as weight changes, especially after bariatric surgery, where requirements can decline during active loss and later recur. [16][19]",
        "For older adults, do not apply BMI-driven loss targets without considering frailty, function, diet quality, and loss of lean mass. Multiple obesity guidelines caution that BMI cutoffs may be less applicable in older adults and that weight-loss goals warrant caution in this population; favor interventions that preserve function and nutrition while addressing clinically important adiposity-related disease. [4][8]"
      ],
      "bullets": [
        "Use serial weights and a preselected clinical target to distinguish maintenance success from clinically important regain.",
        "Continue behavioral contact through the maintenance phase; behavioral support improves long-term outcomes. [19]",
        "In older adults or patients with limited reserve, monitor functional consequences of weight loss and prioritize lean-mass preservation. [4][8]"
      ],
      "subsections": [],
      "table": null
    }
  ],
  "faq": [],
  "references": [
    {
      "number": 1,
      "title": "Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial | Nature Medicine",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41591-025-03556-3",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 2,
      "title": "Differential mechanisms affecting weight loss and weight loss maintenance | Nature Metabolism",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s42255-023-00864-1?fromPaywallRec=false",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 3,
      "title": "Differential mechanisms affecting weight loss and weight loss maintenance",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s42255-023-00864-1",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 4,
      "title": "Clinical practice guidelines for older adults living with overweight and obesity: A scoping review",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S2667268524000354",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 5,
      "title": "iCARDIO Alliance global implementation guidelines for the management of obesity 2025 focus on prevention and treatment of cardiometabolic disease",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S2666667726000395",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 6,
      "title": "Screening for and Management of Obesity in Adults: U.S. ...",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S2049080113700220",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 7,
      "title": "Weight-Loss Outcomes: A Systematic Review and Meta-Analysis of Weight-Loss Clinical Trials with a Minimum 1-Year Follow-Up",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0002822307014836",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 8,
      "title": "Changes in lean body mass with <fc>glucagon‐like peptide</fc>‐1‐based therapies and mitigation strategies",
      "detail": "dom-pubs.onlinelibrary.wiley.com",
      "url": "https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.15728",
      "authors": "dom-pubs.onlinelibrary.wiley.com",
      "host": "dom-pubs.onlinelibrary.wiley.com"
    },
    {
      "number": 9,
      "title": "Weight Loss Plateau: Reasons, Challenges, and Solutions",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/10.1002/hsr2.72803",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com"
    },
    {
      "number": 10,
      "title": "Reduced State: Physiology, Behavior, and Interventions",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/pdf/10.1002/oby.23086",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com"
    },
    {
      "number": 11,
      "title": "Clinical Management of Weight Regain and Cardiometabolic ...",
      "detail": "dom-pubs.onlinelibrary.wiley.com",
      "url": "https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.70713?af=R",
      "authors": "dom-pubs.onlinelibrary.wiley.com",
      "host": "dom-pubs.onlinelibrary.wiley.com"
    },
    {
      "number": 12,
      "title": "Beyond appetite regulation: Targeting energy expenditure ...",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/full/10.1002%2Foby.23374",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com"
    },
    {
      "number": 13,
      "title": "Weight-Loss Plateau during Lifestyle Intervention Predicts ...",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12052359",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 14,
      "title": "Weight Loss Plateau: Reasons, Challenges, and Solutions: A Narrative Review",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13373534",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 15,
      "title": "Management of Weight Loss Plateau - StatPearls - NCBI - NIH",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK576400",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 16,
      "title": "Metabolic Consequences of Weight Reduction - StatPearls - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK572145",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 17,
      "title": "Medical Management of the Post Operative Bariatric Surgery ...",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK481901",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 18,
      "title": "The Carbohydrate-Insulin Model of Obesity: Beyond ‘Calories In, Calories Out’",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6082688",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 19,
      "title": "The Science of Obesity Management: An Endocrine Society Scientific Statement - PMC",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5888222",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 20,
      "title": "Pharmacologic Treatment of Overweight and Obesity in Adults",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK279038",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 21,
      "title": "Randomised Trial of Intensive Behavioral Lifestyle Intervention Versus Usual Preparation for Bariatric Surgery | Cochrane Library",
      "detail": "www.cochranelibrary.com",
      "url": "https://www.cochranelibrary.com/content;jsessionid=97716D29E5912EDD03C6CF974BB87DB3;jsessionid=DA8713AF473E2243E2A05AB03DA062F1?templateType=related&urlTitle=%2Fcentral%2Fdoi%2F10.1002%2Fcentral%2FCN-02082715&doi=10.1002%2Fcentral%2FCN-02082715&p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&_scolariscontentdisplay_WAR_scolariscontentdisplay_action=related-content&p_p_lifecycle=0&p_p_mode=view&type=central&contentLanguage=",
      "authors": "www.cochranelibrary.com",
      "host": "www.cochranelibrary.com"
    },
    {
      "number": 22,
      "title": "Weight Loss with Combination Anti-Obesity Medications Approximates that Achieved with Bariatric Surgery - Endocrine News",
      "detail": "endocrinenews.endocrine.org",
      "url": "https://endocrinenews.endocrine.org/weight-loss-with-combination-anti-obesity-medications-approximates-that-achieved-with-bariatric-surgery",
      "authors": "endocrinenews.endocrine.org",
      "host": "endocrinenews.endocrine.org"
    },
    {
      "number": 23,
      "title": "Executive Summary of the Clinical Guidelines on ...",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S0002822398002764",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 24,
      "title": "Novel strategies for medical management of obesity",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S0002916525003375",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    }
  ],
  "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.",
  "citations": [
    {
      "number": 1,
      "title": "Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial | Nature Medicine",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41591-025-03556-3",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "Expert panels have recommended the addition of anti-obesity medications (AOMs) approved for chronic weight management for individuals with a body mass index (BMI) ≥ 30 kg m−2 (or BMI ≥ 27 kg m−2 with comorbidity) who are unable to lose weight or sustain weight loss with BT alone1.\"),2.\"). For exampl",
      "score": 0.5345888
    },
    {
      "number": 2,
      "title": "Differential mechanisms affecting weight loss and weight loss maintenance | Nature Metabolism",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s42255-023-00864-1?fromPaywallRec=false",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "This Perspective is a comparison of the interactions of weight loss and maintenance with genetic, behavioural, physiological and environmental homeostatic systems and a discussion of the implications of these findings for research in, and treatment of, obesity. ### Obesity-induced and weight-loss-in",
      "score": 0.66959417
    },
    {
      "number": 3,
      "title": "Differential mechanisms affecting weight loss and weight loss maintenance",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s42255-023-00864-1",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "Differential mechanisms affecting weight loss and weight loss maintenance | Nature Metabolism. This Perspective is a comparison of the interactions of weight loss and maintenance with genetic, behavioural, physiological and environmental homeostatic systems and a discussion of the implications of th",
      "score": 0.63615024
    },
    {
      "number": 4,
      "title": "Clinical practice guidelines for older adults living with overweight and obesity: A scoping review",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S2667268524000354",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "Of the 23 guidelines, nine included text specific for older adults. Of these guidelines, four contained cautions regarding relevance of body mass index (BMI) cutoffs for older adults, and an additional two guidelines contained statements that BMI is a poor predictor of mortality. Information on wais",
      "score": 0.51105833
    },
    {
      "number": 5,
      "title": "iCARDIO Alliance global implementation guidelines for the management of obesity 2025 focus on prevention and treatment of cardiometabolic disease",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S2666667726000395",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "There are a number of guidelines on how to manage obesity, but inconsistencies in healthcare access, varying infrastructure, resource constraints and diverse local practices restrict their global applicability. This underscores the need for universal recommendations that address the unique challenge",
      "score": 0.48030865
    },
    {
      "number": 6,
      "title": "Screening for and Management of Obesity in Adults: U.S. ...",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S2049080113700220",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "by A Yao · 2013 · Cited by 16 — The NHMRC recommends behaviour intervention with nutrition and physical activity integrated into all weight loss programmes. However, the recommendation is",
      "score": 0.44015694
    },
    {
      "number": 7,
      "title": "Weight-Loss Outcomes: A Systematic Review and Meta-Analysis of Weight-Loss Clinical Trials with a Minimum 1-Year Follow-Up",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0002822307014836",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "### JAMA (2002) \n   K.M. Flegal _et al._\n### Overweight and obesity in the United States: Prevalence and trends, 1960-1994\n\n### Int J Obes Relat Metab Disord (1998) \n   E.C. Weis _et al._\n### Weight-control practices among US adults, 2001-2002\n\n### Am J Prev Med (2006) \n   G.D. Foster _et al._\n### W",
      "score": 0.37093207
    },
    {
      "number": 8,
      "title": "Changes in lean body mass with <fc>glucagon‐like peptide</fc>‐1‐based therapies and mitigation strategies",
      "detail": "dom-pubs.onlinelibrary.wiley.com",
      "url": "https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.15728",
      "authors": "dom-pubs.onlinelibrary.wiley.com",
      "host": "dom-pubs.onlinelibrary.wiley.com",
      "snippet": "There is an established association between body weight and muscle mass. Persons living with obesity commonly have more muscle mass than those with normal weight, and weight loss (from any intervention) is associated with loss of muscle mass. Weight loss from diet, pharmacotherapy, surgery or diseas",
      "score": 0.44869256
    },
    {
      "number": 9,
      "title": "Weight Loss Plateau: Reasons, Challenges, and Solutions",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/10.1002/hsr2.72803",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com",
      "snippet": "Weight loss plateau (WLP) is one of the most significant obstacles for individuals with overweight and obesity during weight loss (WL).",
      "score": 0.41591915
    },
    {
      "number": 10,
      "title": "Reduced State: Physiology, Behavior, and Interventions",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/pdf/10.1002/oby.23086",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com",
      "snippet": "by LJ Aronne · 2021 · Cited by 147 — The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: A multi- center study. Surg Obes",
      "score": 0.3961388
    },
    {
      "number": 11,
      "title": "Clinical Management of Weight Regain and Cardiometabolic ...",
      "detail": "dom-pubs.onlinelibrary.wiley.com",
      "url": "https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.70713?af=R",
      "authors": "dom-pubs.onlinelibrary.wiley.com",
      "host": "dom-pubs.onlinelibrary.wiley.com",
      "snippet": "Adaptive Thermogenesis Energy expenditure decreases disproportionately to changes in body mass during weight loss, a phenomenon termed adaptive",
      "score": 0.35561875
    },
    {
      "number": 12,
      "title": "Beyond appetite regulation: Targeting energy expenditure ...",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/full/10.1002%2Foby.23374",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com",
      "snippet": "by BØ Christoffersen · 2022 · Cited by 162 — Weight-loss trajectories with current and future therapies. Lifestyle interventions produce modest weight loss followed by weight regain.",
      "score": 0.30194885
    },
    {
      "number": 13,
      "title": "Weight-Loss Plateau during Lifestyle Intervention Predicts ...",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12052359",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "by L Luo · 2025 · Cited by 1 — The diagnostic threshold for identifying fatty liver was established at an average LFC of ≥5.0%. Fatty liver severity was classified as mild (5–10%), moderate",
      "score": 0.4108041
    },
    {
      "number": 14,
      "title": "Weight Loss Plateau: Reasons, Challenges, and Solutions: A Narrative Review",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13373534",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "Individuals undergoing moderate calorie restriction report experiencing WLP within 12 weeks . However, a meta‐analysis of eight WL strategies, including diet alone, diet combined with exercise, exercise alone, meal replacements, very‐low‐energy diets, and weight‐loss medications (such as orlistat an",
      "score": 0.32241982
    },
    {
      "number": 15,
      "title": "Management of Weight Loss Plateau - StatPearls - NCBI - NIH",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK576400",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "Regardless of the type of diet, plateaus occur weeks to months following the initiation of a weight management program. The American College of Cardiology (ACC) and the American Heart Association (AHA) indicate individuals generally achieve maximal weight loss at 6 months, followed by weight mainten",
      "score": 0.2465111
    },
    {
      "number": 16,
      "title": "Metabolic Consequences of Weight Reduction - StatPearls - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK572145",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "Weight Loss Plateau and Patient Discouragement\n\nThe weight-loss plateau, typically occurring around 6 to 8 months, results from a combination of factors, including metabolic adaptation and hormonal changes that promote appetite and increased caloric intake. Patients and clinicians may mistake these ",
      "score": 0.23725812
    },
    {
      "number": 17,
      "title": "Medical Management of the Post Operative Bariatric Surgery ...",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK481901",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "for most patients regardless of procedure. Postoperative laboratory monitoring should include 25-hydroxyvitamin D, calcium, albumin, phosphorus, and PTH levels. The vitamin D supplement dose can be titrated to achieve and maintain a 25-hydroxyvitamin D level of at least 30 ng/mL. If secondary hyperp",
      "score": 0.171755
    },
    {
      "number": 18,
      "title": "The Carbohydrate-Insulin Model of Obesity: Beyond ‘Calories In, Calories Out’",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6082688",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "glycosuria.6 Conversely, inadequate insulin treatment of type 1 diabetes and drugs that inhibit insulin secretion7 cause weight loss. [...] Disclaimer: The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Instit",
      "score": 0.14629474
    },
    {
      "number": 19,
      "title": "The Science of Obesity Management: An Endocrine Society Scientific Statement - PMC",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5888222",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "#### Nonalcoholic fatty liver disease\n\nFatty liver disease is often associated with obesity (196). Excess liver fat without inflammation/hepatocellular injury is called nonalcoholic fatty liver disease (NAFLD), which may progress to nonalcoholic steatohepatitis (NASH) and eventually cirrhosis. The d",
      "score": 0.13849701
    },
    {
      "number": 20,
      "title": "Pharmacologic Treatment of Overweight and Obesity in Adults",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK279038",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "## MEDICATION-INDUCED OBESITY\n\nThe role of medications as a factor that can induce weight gain is often overlooked. Several commonly prescribed medications as well as over-the-counter medications are associated with significant weight gain. These include medications used to treat T2D, hypertension, ",
      "score": 0.1287991
    },
    {
      "number": 21,
      "title": "Randomised Trial of Intensive Behavioral Lifestyle Intervention Versus Usual Preparation for Bariatric Surgery | Cochrane Library",
      "detail": "www.cochranelibrary.com",
      "url": "https://www.cochranelibrary.com/content;jsessionid=97716D29E5912EDD03C6CF974BB87DB3;jsessionid=DA8713AF473E2243E2A05AB03DA062F1?templateType=related&urlTitle=%2Fcentral%2Fdoi%2F10.1002%2Fcentral%2FCN-02082715&doi=10.1002%2Fcentral%2FCN-02082715&p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&_scolariscontentdisplay_WAR_scolariscontentdisplay_action=related-content&p_p_lifecycle=0&p_p_mode=view&type=central&contentLanguage=",
      "authors": "www.cochranelibrary.com",
      "host": "www.cochranelibrary.com",
      "snippet": "Randomised Trial of Intensive Behavioral Lifestyle Intervention Versus Usual Preparation for Bariatric Surgery | Cochrane Library. ### Cochrane review language. Select your preferred language for Cochrane reviews and other content. Select your preferred language for the Cochrane Library website. _Co",
      "score": 0.5849357
    },
    {
      "number": 22,
      "title": "Weight Loss with Combination Anti-Obesity Medications Approximates that Achieved with Bariatric Surgery - Endocrine News",
      "detail": "endocrinenews.endocrine.org",
      "url": "https://endocrinenews.endocrine.org/weight-loss-with-combination-anti-obesity-medications-approximates-that-achieved-with-bariatric-surgery",
      "authors": "endocrinenews.endocrine.org",
      "host": "endocrinenews.endocrine.org",
      "snippet": "Endocrine News\n\nEndocrine News\n\n# Weight Loss with Combination Anti-Obesity Medications Approximates that Achieved with Bariatric Surgery\n\nWeight loss achieved through the use of a combination of anti-obesity medications (AOMs) can approach the reduction seen in bariatric surgery, according to a pap",
      "score": 0.42663267
    },
    {
      "number": 23,
      "title": "Executive Summary of the Clinical Guidelines on ...",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S0002822398002764",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "by THEN HEART · 1998 · Cited by 41 — It should focus on altering dietary and physical activity patterns to prevent development of obesity and to produce moderate weight loss. The panel reviewed",
      "score": 0.36895174
    },
    {
      "number": 24,
      "title": "Novel strategies for medical management of obesity",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S0002916525003375",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "Previous article in issue\n   Next article in issue\n\n## Keywords\n\nobesity\n\nnutrition\n\nglucagon-like peptide-1\n\nglucagon-like reptide-1 receptor agonist\n\naddiction\n\ntype 2 diabetes\n\nweight loss\n\nmedicare\n\n## Abbreviations\n\nAgRP\n\nagouti-related peptide\n\nAHI\n\napnea-hyponea index\n\nAOM\n\nantiobesity medica",
      "score": 0.33021247
    }
  ],
  "publishedAt": "2026-08-24T16:44:55.289962+00:00",
  "updatedAt": "2026-08-24T16:44:55.289962+00:00",
  "readingMinutes": 8,
  "slug": "weight-loss-plateau"
}